The oncology nutrition market size is projected to be valued at US$ 2.07 billion in 2023 and is expected to be valued at US$ 4.87 billion by 2033. The demand for oncology nutrition is likely to record an average CAGR of 8.9% during the forecast period.
Medical nutrition therapy for cancer is crucial for enhancing physical capacity, coping with cancer therapies, and overall quality of life. For businesses functioning in contemporary oncology nutrition products, the fall in tolerance to cancer therapy is anticipated to boost the adoption of oncology nutrition. Furthermore, nutritional screening and evaluation are essential for identifying people who are more likely to be malnourished.
Oncology Nutrition Market Trend Analysis
| Report Attribute | Details |
|---|---|
| Oncology Nutrition Market Revenue (2023) | US$ 2.07 billion |
| Market Anticipated Forecast Value (2033) | US$ 4.87 billion |
| Market Projected Growth Rate (2023 to 2033) | 8.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Due to technological developments and extensive research, the cancer nutrition supplements market share is anticipated to expand significantly over the next few years. The demand for oncology nutrition is anticipated to pick up steam throughout the evaluation period, even if the nutritional risk is still mostly beneath the radar.
| Attributes | Details |
|---|---|
| Oncology Nutrition Market Size (2018) | US$ 1.33 billion |
| Market Size (2022) | US$ 1.92 billion |
| Market (CAGR 2018 to 2022) | 7.6% |
Due to the worldwide increase in cases of malnutrition brought on by tumors, oncology nutrition is still a crucial topic for healthcare professionals. According to several studies, malnutrition screening in cancer treatment could enhance nutritional evaluation and help patients avoid malnutrition.
Growth Driving Factors in the Oncology Nutrition Market
A significant driver of the cancer nutrition market's growth is projected to be the huge increase in nutritional waste and nutritional risk among cancer patients. Participants in the market landscape are now investigating the possible advantages of utilizing a multidisciplinary strategy, where focused oncology nutrition guidelines are expected to be crucial to improving the standard of cancer care.
The oncology nutrition companies are anticipated to profit from increased research and development activities as well as the launch of cutting-edge products for cancer patients over the forecasted period. The creation of essential formulas and the advent of new markets are also anticipated to boost the cancer nutrition patent landscape and the pace of future expansion.
Due to these factors, the overall market is anticipated to reach US$ 3.12 billion by the end of 2027. A few key aspects anticipated to drive the expansion of the market for oncology nutrition research in the upcoming years include:
Due to the considerable increase in the use of nutritional evaluation programs, particularly during cancer cachexia and pre-cachexia, the demand for oncology nutrition is predicted to continue to rise. Over the past ten years, data-gathering methods for varied patients' nutritional status have advanced quickly. These developments have led to personalized oncology nutrition therapy and are now recognized as the perfect remedy for cancer patients prone to malnutrition.
Principal Consultant
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The gastrointestinal cancer sector is expected to develop over the research period due to the high incidence of this cancer in the global population.
| Attributes | Details |
|---|---|
| Top Cancer Type | Gastrointestinal Cancer |
| Market Share in 2023 | 22.2% |
This situation has led to the growth of gastrointestinal cancer nutritional supplements and increased awareness of the importance of nutritional supplement use.
The demand for oncology nutrition is growing because diet provides the ability to fight disease and provides power and endurance against the treatment's side effects.
| Attributes | Details |
|---|---|
| Top Route of Administration Type | Enteral Nutrition |
| Market Share in 2023 | 73% |
As the number of individuals diagnosed with cancer rises, medical professionals will likely favor the enteral nutrition segment.
The requirement of appropriate medication strategy and prescriptions has resulted in higher sales of all nutrition and supplements market products through hospitals and clinic segments.
| Attributes | Details |
|---|---|
| Top Distribution Channel Type | Hospitals and Clinics |
| Market Share in 2023 | 46.8% |
So, as per our estimates, this segment is anticipated to remain the leading distribution channel for oncology nutrition products as well through 2033.
North America is anticipated to lead the global oncology nutrition market throughout the forecast period. This is due to several important factors, including the increased incidence of cancer and the accessibility of cutting-edge healthcare infrastructure.
The oncology nutrition market in the United States is expected to be worth around US$ 412.6 million. According to a statistic from the American Cancer Society, there will likely be 1.9 million new instances of cancer in the United States this year.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 33.4% |
| Europe | 28.8% |
FMI projects that the Asia Pacific oncology nutrition market is anticipated to expand faster due to the region's rising prevalence of cancer cases. Additionally, several certification programs and awareness sessions are held locally to inform cancer patients and healthcare professionals about the significance of oncology nutrition.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| United States | 29.7% |
| Germany | 7.9% |
| Japan | 3.4% |
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 8.3% |
| China | 11.9% |
| India | 9.4% |
| Australia | 9.6% |
With certain leading pharmaceutical corporations, startups in the oncology nutrition sector are working hard in this area. Clinical studies now include parenteral oncology feeding. Oncology nutrition is projected to become more popular as cancer incidence and the demand for tailored medication and nutrition rise.
In the market for cancer nutrition, collaboration with nutritionists and oncology research institutes is also anticipated to present considerable prospects for companies. For instance, the American biotechnology giant Celgene Corporation teamed up with Savor Health, a provider of specialized nutritional advice to cancer patients.
New product launches and continuous technological innovations are the key strategies adopted by prominent players in the oncology nutrition market. The healthcare systems organizations are changing due to new research and increased public knowledge of the advantages of oncology nutrition. Clinical nutritionists and oncologists are working more closely to improve oncology nutrition and treatment within the oncology nutrition sector.
The presence of competitors, new product debuts, and partnerships related to the industry under consideration all contribute to the market's growth. According to the report, Esperer launched its nutrition development center in Hyderabad in 2020. The facility in Hyderabad is expected to house a variety of cohesive capabilities, such as investigative workrooms and product development sub-centers, with a dedicated laboratory for analyzing sensory components, packing, and taste.
The leading firms worldwide for oncology nutrition are focused on obtaining regulatory clearances, developing cutting-edge goods, introducing new products, and partnering with and acquiring other businesses. The global market for oncology nutrition is projected to expand due to these leading players' tactics. The following are a few expansion methods used by companies in the oncology nutrition market:
| Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8.9% from 2023 to 2033 |
| Base Year of Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and F-CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, growth factors, Trends, and Pricing Analysis |
| Key Segments Covered | By Cancer Type, By End Use, By Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; The Middle East & Africa; Oceania |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, Italy, France, United Kingdom, Spain, Russia, China, Japan, GCC Countries, Australia |
| Key Companies Profiled | FMC Corporation; Danone India; Abbott; Aceto; B. Braun Melsungen AG; Baxter; Fresenius Kabi AG; Global Health Products, Inc.; Hormel Foods Corporation; Mead Johnson & Company, LLC; Meiji Holdings Co., Ltd; Nestlé S.A.; BioSig Technologies, Inc.; Auris Health, Inc. |
The overall market is estimated to be around US$ 2.07 billion in 2023.
FMC, Danone, and Abbott are some of the leading market players.
Proper management of diet intake of patients undergoing cancer treatment.
The hospitals and clinical market segment contributed 46.8% of revenue in 2022.
Collaborations with nutritionists and oncology research institutes are driving the market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Cancer Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Cancer Type, 2023 to 2033
5.3.1. Head & Neck Cancer
5.3.2. Stomach & Gastrointestinal Cancers
5.3.3. Blood Cancer
5.3.4. Breast Cancer
5.3.5. Lung Cancer
5.3.6. Other cancers
5.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Cancer Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033
6.3.1. Hospitals
6.3.2. Home Care
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Cancer Type
8.2.3. By End Use
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Cancer Type
8.3.3. By End Use
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Cancer Type
9.2.3. By End Use
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Cancer Type
9.3.3. By End Use
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Cancer Type
10.2.3. By End Use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Cancer Type
10.3.3. By End Use
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Cancer Type
11.2.3. By End Use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Cancer Type
11.3.3. By End Use
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Cancer Type
12.2.3. By End Use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Cancer Type
12.3.3. By End Use
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Cancer Type
13.2.3. By End Use
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Cancer Type
13.3.3. By End Use
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Cancer Type
14.2.3. By End Use
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Cancer Type
14.3.3. By End Use
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Cancer Type
15.1.2.2. By End Use
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Cancer Type
15.2.2.2. By End Use
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Cancer Type
15.3.2.2. By End Use
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Cancer Type
15.4.2.2. By End Use
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Cancer Type
15.5.2.2. By End Use
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Cancer Type
15.6.2.2. By End Use
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Cancer Type
15.7.2.2. By End Use
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Cancer Type
15.8.2.2. By End Use
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Cancer Type
15.9.2.2. By End Use
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Cancer Type
15.10.2.2. By End Use
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Cancer Type
15.11.2.2. By End Use
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Cancer Type
15.12.2.2. By End Use
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Cancer Type
15.13.2.2. By End Use
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Cancer Type
15.14.2.2. By End Use
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Cancer Type
15.15.2.2. By End Use
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Cancer Type
15.16.2.2. By End Use
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Cancer Type
15.17.2.2. By End Use
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Cancer Type
15.18.2.2. By End Use
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Cancer Type
15.19.2.2. By End Use
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Cancer Type
15.20.2.2. By End Use
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Cancer Type
15.21.2.2. By End Use
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Cancer Type
15.22.2.2. By End Use
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Cancer Type
15.23.2.2. By End Use
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Cancer Type
16.3.3. By End Use
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. FMC Corporation
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Danone India
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Abbott
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Aceto
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. B. Braun Melsungen AG
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Baxter
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Fresenius Kabi AG
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Global Health Products, Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Hormel Foods Corporation
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Mead Johnson & Company, LLC
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Meiji Holdings Co., Ltd
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Nestlé S.A.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. BioSig Technologies, Inc.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. Auris Health, Inc.
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Oncology Nutrition Market
